Due to a high load of modelling projects, the rate of submission via the website has been reduced.
For a much higher submission rate, please use the Modelling API.

SMTL ID : 6dcg.1

Discovery of MK-8353: An Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology

Coordinates
PDB Format
Method
X-RAY DIFFRACTION 1.45 Å
Oligo State
monomer
Ligands
2 x SO4: SULFATE ION(Non-functional Binders)
1 x G67: (3S)-3-(methylsulfanyl)-1-(2-{4-[4-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl]-3,6-dihydropyridin-1(2H)-yl}-2-oxoethyl)-N-(3-{6-[(propan-2-yl)oxy]pyridin-3-yl}-1H-indazol-5-yl)pyrrolidine-3-carboxamide(Non-covalent)
Links
RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP
Citation
Boga, S.B. et al., MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology. ACS Med Chem Lett (2018)
Release Date
2018-08-08
Peptides
Mitogen-activated protein kinase 1: A
SMTL:PDB
SMTL Chain Id:
PDB Chain Id:
A
A

Mitogen-activated protein kinase 1

Related Entries With Identical Sequence

2z7l.1 | 5ke0.1 | 5u6i.1 | 6cpw.1